The New England journal of medicine
-
Meta Analysis
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined. ⋯ Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.
-
Letter Case Reports
Atrophic glossitis leading to the diagnosis of celiac disease.